ELLO

Business Context and Reporting Period

Company: NUR Macroprinters Ltd. (Ellomay Capital Ltd. is not the registrant; the filing is for NUR Macroprinters Ltd.)
Reporting Period: Fiscal year ended December 31, 2005
Business Overview: NUR is a leading supplier of wide format and super wide format digital printing systems (printers) and related consumables (inks). The company operates globally with subsidiaries in Europe, North America, South America, and the Asia Pacific region. Manufacturing is centralized in Israel.
Listing Status: Delisted from the Nasdaq Capital Market on May 19, 2005, due to failure to meet minimum stockholders' equity requirements. Shares are currently quoted on the OTC "Pink Sheets" under the symbol "NURM.PK."

Key Financial Metrics (Year Ended Dec 31, 2005)

Material Changes vs. Prior Period

• Revenue Decline: Total revenues decreased by 7.0% ($5.3 million) compared to 2004. This was primarily driven by a decrease in sales in North and South America and a decline in Europe, attributed to the company's unstable financial situation in the second half of 2005.
• Improved Gross Margin: Gross margin improved significantly from 21.1% to 27.2%. This was largely due to a substantial reduction in inventory write-offs, which dropped from $9.7 million in 2004 to $2.7 million in 2005.
• Reduced Net Loss: Net loss narrowed by 33% to $14.7 million. Key drivers included the reduction in inventory write-offs and a reversal of doubtful accounts expense (income of $1.1 million in 2005 vs. expense of $6.3 million in 2004) due to aggressive collection efforts.
• Debt Restructuring: In September 2005, the company entered a debt restructuring agreement with its lender banks. $14.5 million of debt was converted into 8 million warrants, and $5 million was converted into subordinated notes. The remaining debt was refinanced.
• Capital Raise: In October 2005, the company raised $12 million through a private placement led by Fortissimo Capital Fund. As of December 31, 2005, only the first installment of $5 million had been received.

Guidance, Outlook, Risks, and Unusual Items

• Outlook: Management expects revenues to increase in 2006 across all geographical regions, driven by the release of new products (NUR Expedio 3200 and NUR Tempo II). A cost reduction plan is expected to further improve gross margins.
• Unusual Items:
  • Warrant Expense: A non-operating expense of $1.4 million was recorded for the fair value of warrants issued to a former director (Dan Purjes) in connection with a voting agreement.
  • Restatement: Financial statements for 2002-2004 were restated due to changes in revenue recognition policies and deferred tax valuation.
• Key Risks:
  • Liquidity: The company has incurred operating losses for five consecutive years and may require additional funding. Failure to raise funds could halt R&D and operations.
  • Debt Covenants: The company must maintain specific financial ratios (Debt to EBITDA) starting in 2008. Failure to comply could trigger immediate repayment of all loans.
  • Market Liquidity: Trading on the Pink Sheets is subject to "penny stock" regulations, limiting liquidity and potentially depressing share prices.
  • Legal Proceedings: The company faces various lawsuits regarding product quality and royalty disputes with government authorities (OCS and Marketing Fund), though settlements have been reached for some.
  • Internal Controls: Management identified material weaknesses in internal controls related to revenue recognition and allowance for doubtful accounts, which are being addressed.

Important Facts for Investor Verification

• Debt Covenant Compliance: Verify the company's ability to meet the new Debt-to-EBITDA covenants (13:1 in 2008, decreasing to 6:1 by 2011) to avoid default.
• Capital Raise Completion: Confirm the receipt of the remaining $7 million from the Fortissimo private placement (scheduled for 2006).
• Inventory Valuation: Monitor future inventory write-offs, as the 2005 improvement was heavily influenced by a reduction in these charges rather than operational efficiency alone.
• Legal Settlements: Track the status of ongoing litigation and the payment schedule for the settled government royalty disputes ($0.6 million to OCS and $0.78 million to Marketing Fund).
• Internal Control Remediation: Assess the effectiveness of the new policies implemented to address the material weaknesses in revenue recognition and financial reporting.